SCHEMBL788329

SCHEMBL788329

O=C(O)c1nc2c(N3CCC(n4c(=O)[nH]c5ccccc54)CC3)ncnc2n1C1CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 1/20 0.67
▸ PIK3R1 P27986 1/20 0.67
▸ OPRM1 P35372 2/20 0.47
▸ OPRK1 P41145 1/20 0.47
▸ OPRL1 P41146 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ PMP22 Q01453 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ CHRM1 P11229 4/20 0.47
▸ CHRM2 P08172 3/20 0.47
▸ CHRM4 P08173 3/20 0.47
▸ CHRM3 P20309 2/20 0.47
▸ HSD11B1 P28845 4/20 0.46
▸ DRD2 P14416 1/20 0.46
▸ KCNH2 Q12809 1/20 0.46
▸ SLC18A3 Q16572 1/20 0.46
▸ PLD2 O14939 1/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ AKT1 P31749 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL788325 0.92 PIK3CD (0.76) PIK3CDPIK3R1OPRM1OPRK1OPRL1
SCHEMBL18167366 0.87 PIK3CD (0.68) PIK3CDPIK3R1OPRM1OPRK1OPRL1
SCHEMBL794661 0.87 PIK3CD (0.85) PIK3CDPIK3R1PLD2MAPK1LMNA
SCHEMBL15485458 0.86 PIK3CD (0.79) PIK3CDPIK3R1OPRM1ALDH1A1KDM4E
SCHEMBL806209 0.86 PIK3CD (0.70) PIK3CDPIK3R1OPRM1ALDH1A1KDM4E
SCHEMBL18175803 0.84 PIK3CD (0.74) PIK3CDPIK3R1OPRM1OPRK1OPRL1
SCHEMBL788143 0.84 PIK3CD (0.81) PIK3CDPIK3R1ALDH1A1KDM4EPMP22
SCHEMBL788360 0.84 PIK3CD (0.75) PIK3CDPIK3R1OPRM1ALDH1A1KDM4E
SCHEMBL787863 0.83 PIK3CD (0.82) PIK3CDPIK3R1ALDH1A1KDM4EPMP22
SCHEMBL794245 0.83 PIK3CD (0.72) PIK3CDPIK3R1ALDH1A1KDM4EPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616469-B1 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE EXELIXIS INC (US) 2016-10-26 — — EP disclosed
US-9346807-B2 Inhibitors of PI3K-delta and methods of their use and manufacture EXELIXIS, INC. (US) 2016-05-24 — — US disclosed
US-9346807-B2 Inhibitors of PI3K-delta and methods of their use and manufacture EXELIXIS, INC. (US) 2016-05-24 — — US disclosed
US-9346807-B2 Inhibitors of PI3K-delta and methods of their use and manufacture EXELIXIS, INC. (US) 2016-05-24 — — US disclosed
US-20140058103-A1 Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-02-27 — — US disclosed
US-20140058103-A1 Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-02-27 — — US disclosed
US-20140058103-A1 Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-02-27 — — US disclosed
EP-2616469-A1 INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-07-24 — — EP disclosed
WO-2012037226-A1 INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140058103-A1 Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture PIK3CD, PIK3CA, PIK3R5 PIK3CD 1/4885PIK3R1 6/4885OPRM1 2610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback